Drugs / GC012F
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 012 trials | ||||||
| Phase 0 | NCT07315503 | Dec 2027 → Jan 2028 | rheumatoid arthritis | Institute of Hematology & Blood Diseases Hospital, China | Withdrawn | No outcome recorded |
| Phase 0 | NCT07303790 | Mar 2026 → Jan 2027 expected | multiple sclerosis | Daishi Tian | Recruiting | No outcome recorded |
| Phase 0 | NCT07350837 | Jan → Dec 2026 expected | anti-HLA hyperimmunization | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07364487 | Jan → Mar 2026 | multiple sclerosis | Huashan Hospital | Withdrawn | No outcome recorded |
| Phase 0 | NCT07086404 | Sep 2025 → Sep 2027 expected | idiopathic inflammatory myopathy | Daishi Tian | Recruiting | No outcome recorded |
| Phase 0 | NCT07072884 | Aug 2025 → Mar 2027 expected | idiopathic inflammatory myopathy, systemic sclerosis | Qiong Fu | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07058298 | Jul 2025 → Feb 2027 expected | generalized myasthenia gravis | Daishi Tian | Recruiting | No outcome recorded |
| Phase 0 | NCT06419166 | Dec 2024 → Jun 2027 | generalized myasthenia gravis | Zhejiang University | Withdrawn | No outcome recorded |
| Phase 0 | NCT05858684 | May 2023 → Aug 2028 expected | — | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05840107 | May 2023 → Sep 2025 | plasma cell myeloma | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04617704 | Dec 2021 | plasma cell myeloma | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04236011 | Jan 2020 → Jul 2022 | plasma cell myeloma | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT07295847 | Jan 2026 → Feb 2028 expected | idiopathic inflammatory myopathy, rheumatoid arthritis, systemic sclerosis | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07224373 | Dec 2025 → Dec 2028 expected | multiple sclerosis | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07250269 | Oct 2025 → Nov 2028 expected | AL amyloidosis | Gracell Biotechnologies (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07073547 | Jul 2025 → May 2028 expected | plasma cell myeloma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06759948 | Feb 2025 → Feb 2027 expected | generalized myasthenia gravis | Chongbo Zhao | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05846347 | May → Oct 2023 | — | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05412329 | Jun 2022 → Jun 2024 | plasma cell myeloma | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07081646 | Aug 2025 → Aug 2029 expected | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06897930 | Apr 2025 → May 2029 expected | systemic lupus erythematosus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06235229 | Dec 2023 → Mar 2026 overdue | plasma cell myeloma | Gracell Biotechnologies (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05850234 | Jul 2023 → Aug 2027 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04935580 | Jun 2021 → Jul 2023 | plasma cell myeloma | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07391657 | Feb 2026 → Jun 2028 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC012F | “A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or...” NCT07081646 ↗18“AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor-T Cell (CAR-T) Therapy” NCT07350837 ↗ |
| Known as | AZD0120 | “GC012F, now renamed AZD0120, is an autologous B-cell maturation antigen and CD19 dual-targeting chimeric antigen receptor (CAR) T-cell product manufactured on the FasTCAR platform.” PMID 41925575 ↗ Jun 2026 |
| Known as | CD19-BCMA CAR-T cells | “GC012F injection (CD19-BCMA CAR-T cells)” NCT05846347 ↗1“Other Name: CD19-BCMA CAR-T cells” NCT06419166 ↗ |
| Known as | GC012F injection | “GC012F injection is an autologous dual CAR-T targeted BCMA and CD19.” NCT04935580 ↗1“Drug: GC012F injection” NCT06759948 ↗ |
| Action | Deplete | “CD19- BCMA CAR-T cells can theoretically completely deplete abnormal antibody-producing B cells” NCT05858684 ↗ |
| Modality | Cell therapy | “autologous dual chimeric antigen receptor T-cell (CAR-T) therapy” NCT04236011 ↗ |
| Route | Intravenous | “administered intravenously” NCT04236011 ↗ |
| Target | CD19 | “GC012F is an autologous dual chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) and CD19.” NCT04236011 ↗ |